Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kudgus, Rachel A ^a   Walden, Chad A ^a   McGovern, Renee M ^a   Reid, Joel M ^a   Robertson, J David ^b   Mukherjee, Priyabrata ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; GOLD; METAL NANOPARTICLE; NANOCONJUGATE;

ANIMAL; AREA UNDER THE CURVE; DRUG DELIVERY SYSTEM; HALF LIFE TIME; MALE; METABOLISM; MOUSE; PHYSIOLOGY; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; GOLD; HALF-LIFE; MALE; METAL NANOPARTICLES; MICE; NANOCONJUGATES; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84904321143     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05669     Document Type: Article

References (45)

1. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews. Drug discovery 9, 615-627, doi:10.1038/nrd2591 (2010).
2. Bhattacharyya, S., Kudgus, R. A., Bhattacharya, R. & Mukherjee, P. Inorganic nanoparticles in cancer therapy. Pharmaceutical research 28, 237-259, doi:10.1007/s11095-010-0318-0 (2011).
3. Kudgus, R. A., Bhattacharya, R. & Mukherjee, P. Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem 11, 965-973 (2011).
4. Arvizo, R. R. et al. Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future. Chemical Society reviews 41, 2943-2970, doi:10.1039/c2cs15355f (2012).
5. Doane, T. & Burda, C. Nanoparticle mediated non-covalent drug delivery. Adv Drug Deliv Rev 65, 607-621, doi:10.1016/j.addr.2012.05.012 (2013).
6. Khan, J. A. et al. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. Plos One 6, e20347, doi:10.1371/journal.pone.0020347 (2011).
7. Li, S. D. & Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Molecular pharmaceutics 5, 496-504, doi:10.1021/mp800049w (2008).
8. Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65, 71-79, doi:10.1016/j.addr.2012.10.002 (2013).
9. Lammers, T., Kiessling, F., Hennink, W. E. & Storm, G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. Journal of controlled release: official journal of the Controlled Release Society 161, 175-187, doi:10.1016/j.jconrel.2011.09.063 (2012).
10. Huang, Y., Goel, S., Duda, D. G., Fukumura, D. & Jain, R. K. Vascular normalizationasanemerging strategytoenhance cancer immunotherapy. Cancer Res 73, 2943-2948, doi:10.1158/0008-5472.CAN-12-4354 (2013).
11. Fay, F. & Scott, C. J. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy 3, 381-394, doi:10.2217/imt.11.5 (2011).
12. Steichen, S.D.C.-M., Mary;Peppas, Nicholas, A.Vol. 48/3 416-427 (EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013).
13. Mukherjee, P. et al. Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis. Journal of nanobiotechnology 5, 4, doi:10.1186/1477-3155-5-4 (2007). (Pubitemid 46851043)
14. Choi, C. H., Alabi, C. A., Webster, P. & Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 107, 1235-1240, doi:10.1073/pnas.0914140107 (2010).
15. Wang, J., Sui, M. & Fan, W. Nanoparticles for tumor targeted therapies and their pharmacokinetics. Current drug metabolism 11, 129-141 (2010).
16. Dreaden, E. C., Mwakwari, S. C., Sodji, Q. H., Oyelere, A. K. & El-Sayed, M. A. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjugate chemistry 20, 2247-2253, doi:10.1021/bc9002212 (2009).
17. Brown, S. D. et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. Journal of the American Chemical Society 132, 4678-4684, doi:10.1021/ja908117a (2010).
18. Kudgus, R. A. et al. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. Plos One 8, e57522, doi:10.1371/journal.pone.0057522 (2013).
19. Rathos, M. J., Joshi, K., Khanwalkar, H., Manohar, S. M. & Joshi, K. S. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. Journal of translational medicine 10, 161, doi:10.1186/1479-5876-10-161 (2012).
20. Suh, J. et al. PEGylation of nanoparticles improves their cytoplasmic transport. International journal of nanomedicine 2, 735-741 (2007).
21. Patra, C. R. et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 68, 1970-1978, doi:10.1158/0008-5472.CAN-07-6102 (2008). (Pubitemid 351416584)
22. Mangeney, C. et al. Synthesis and properties of water-soluble gold colloids covalently derivatized with neutral polymer monolayers. J Am Chem Soc 124, 5811-5821 (2002). (Pubitemid 34533521)
23. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature nanotechnology 2, 469-478, doi:10.1038/nnano. 2007.223 (2007). (Pubitemid 47220069)
24. Medintz, I. L., Uyeda, H. T., Goldman, E. R. & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nature materials 4, 435-446, doi:10.1038/nmat1390 (2005). (Pubitemid 40774047)
25. Fang, J., Nakamura, H. & Maeda, H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63, 136-151, doi:10.1016/j.addr. 2010.04.009 (2011).
26. Bhattacharya, R., Patra, C., Earl, A. & Wang, S. Vol. 3 224-238 (Nanomedicine: Nanotechnology, Biology and Medicine, 2007).
27. Gibaldi, M. & Perrier, D. Pharmacokinetics, Second Edition (Drugs and the Pharmaceutical Sciences). 409 (1982).
28. Sardar, R., Funston, A. M., Mulvaney, P. & Murray, R. W. Gold Nanoparticles: Past, Present, and Future. Langmuir 25, 13840-13851 (2009).
29. Simpson, C. A., Huffman, B. J., Gerdon, A. E. & Cliffel, D. E. Unexpected toxicity of monolayer protected gold clusters eliminated by PEG-thiol place exchange reactions. Chemical research in toxicology 23, 1608-1616, doi:10.1021/tx100209t (2010).
30. Zhang, G. et al. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 30, 1928-1936, doi:10.1016/j.biomaterials.2008.12.038 (2009).
31. Masumori, N. et al. Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer. Japanese journal of clinical oncology 38, 182-185, doi:10.1093/jjco/ hym171 (2008). (Pubitemid 351419741)
32. Goldwyn, R. M. Gray's anatomy. Plastic and reconstructive surgery 76, 147-148 (1985).
33. Lai, S. K., Wang, Y. Y., Wirtz, D. & Hanes, J. Micro-and macrorheology of mucus. Adv Drug Deliv Rev 61, 86-100, doi:10.1016/j.addr.2008. 09.012 (2009).
34. Simpson, C. A., Salleng, K. J., Cliffel, D. E. & Feldheim, D. L. In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine: nanotechnology, biology, and medicine 9, 257-263, doi:10.1016/j.nano.2012.06.002 (2013).
35. Ikeda, Y. ,Nagasaki, Y. PEGylation Technology inNanomedicine. Adv Polym Sci 247, 115-140, doi:Doi 10.1007/12-2011-154 (2012).
36. Lipka, J. et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31, 6574-6581, doi:10.1016/j.biomaterials.2010.05.009 (2010).
37. Woodle, M. C. & Lasic, D. D. Sterically stabilized liposomes. Biochimica et biophysica acta 1113, 171-199 (1992).
38. Owens, D. E., 3rd & Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International journal of pharmaceutics 307, 93-102, doi:10.1016/j.ijpharm.2005.10.010 (2006). (Pubitemid 41773257)
39. Li, S. D., Chen, Y. C., Hackett, M. J. & Huang, L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Molecular therapy: the journal of the American Society of Gene Therapy 16, 163-169, doi:10.1038/sj.mt.6300323 (2008).
40. Choi, H. S. et al. Design considerations for tumour-targeted nanoparticles. Nature nanotechnology 5, 42-47, doi:10.1038/nnano.2009.314 (2010).
41. Zhang, X. D. et al. Toxicologic effects of gold nanoparticles in vivo by different administration routes. International journal of nanomedicine 5, 771-781, doi:10.2147/IJN.S8428 (2010).
42. Cho, W. S. et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicology and applied pharmacology 236, 16-24, doi:10.1016/j.taap.2008.12.023 (2009).
43. Balogh, L. et al. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine: nanotechnology, biology, and medicine 3, 281-296, doi:10.1016/j.nano.2007.09.001 (2007). (Pubitemid 350199641)
44. Arvizo, R. R. et al. Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge. Nanomedicine: nanotechnology, biology, and medicine 7, 580-587, doi:10.1016/j.nano.2011.01.011 (2011).
45. Hantash, J., Smidt, M. & Bowsher, R. R. The development, optimization and validation of an ELISA bioanalytical method for the determination of Cetuximab in human serum. Anal Methods-Uk 1, 144-148, doi:Doi 10.1039/B9ay00027c (2009).